Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Axonics, Inc.

Market Cap 3.63B 3.13B 2.89B 2.7B 5.06B 345B 5.14B 34.09B 13.29B 168B 13.61B 13.33B 581B P/E Ratio 2022
-48.9x
P/E Ratio 2023 -502x
Enterprise Value 3.31B 2.86B 2.63B 2.47B 4.62B 315B 4.69B 31.11B 12.13B 153B 12.42B 12.16B 530B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 30/09/2013
Director of Finance/CFO 41 01/10/2023
Chief Operating Officer 47 31/07/2018
Director TitleAgeSince
Director/Board Member 69 31/01/2018
Chairman 55 28/04/2020
Director/Board Member 74 07/04/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.10% - - 3.63B
+2.15%+2.14%-17.25%+10.81% 120B
-0.31%-1.22%+3.56%-4.71% 12.9B
+2.05%+1.45%+29.93%+90.52% 7.44B
+1.87%-4.66%-46.88%-69.45% 4.2B
+2.06%+4.10%+11.98%+37.03% 2.55B
+5.46%+10.04%-15.76%-14.08% 1.8B
+1.67%-5.73%+5.08%-9.77% 1.66B
-8.89%-10.79%+152.96%+119.71% 1.37B
Average +0.67%+0.88%+15.45%+20.01% 18.95B
Weighted average by Cap. +1.82%+1.76%-11.70%+12.08%

Financials

2022 2023
Net sales 274M 236M 218M 204M 382M 26.02B 388M 2.57B 1B 12.66B 1.03B 1.01B 43.84B 366M 316M 292M 273M 512M 34.82B 519M 3.44B 1.34B 16.95B 1.38B 1.35B 58.69B
Net income -59.7M -51.56M -47.51M -44.48M -83.35M -5.67B -84.64M -561M -219M -2.76B -224M -219M -9.56B -6.09M -5.26M -4.85M -4.54M -8.5M -579M -8.63M -57.21M -22.31M -282M -22.85M -22.36M -975M
Net Debt -348M -301M -277M -259M -486M -33.09B -494M -3.27B -1.28B -16.1B -1.31B -1.28B -55.76B -317M -274M -253M -236M -443M -30.16B -450M -2.98B -1.16B -14.68B -1.19B -1.17B -50.84B
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!